AN2 Therapeutics Nominates Novel Boron-Based ENPP1 Inhibitor for Hypophosphatasia Treatment
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced the advancement of AN2-504661, a novel boron-based ENPP1 inhibitor, as a development candidate for treating Hypophosphatasia (HPP). This selection follows extensive lead optimization and preclinical evaluation, which demonstrated AN2-504661's potential for a differentiated profile. Key characteristics include potent and selective ENPP1 inhibition, favorable pharmacokinetic properties, oral bioavailability, efficacy in animal models, and an encouraging nonclinical safety profile with low potential for hERG-related cardiac effects. The company believes this compound has the potential to be a best-in-class treatment. HPP is a rare inherited metabolic bone disease caused by mutations in the ALPL gene, leading to impaired bone and teeth mineralization. The only U.S.-approved therapy for HPP is an injectable enzyme replacement therapy, which requires frequent administration and can cause injection-site reactions. There is currently...
